Ventyx Biosciences Inc (VTYX)

$13.95 -0.02 (-0.14%)
Market Cap 1.00B
Revenue (ttm) 0.00
Net Income (ttm) -135.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,444,000
Avg Vol 3,649,104
Day's Range N/A - N/A
Shares Out 71.76M
Stochastic %K 58%
Beta 1.25
Analysts Hold
Price Target $13.44

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like recept...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 593 4832
Address:
12790 El Camino Real, Suite 200, San Diego, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 8:17 PM
$VTYX RSI: 50.00, MACD: 0.4325 Vol: 0.02, MA20: 13.95, MA50: 12.03 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Etiennec
Etiennec Feb. 23 at 7:59 PM
$VTYX
0 · Reply
Agafon12
Agafon12 Feb. 23 at 7:57 PM
$VTYX Great news for Novo — down 16% today. If anyone has their phone number, call them and tell them there’s Ventyx they can buy for cheap.
0 · Reply
nsomniyak
nsomniyak Feb. 23 at 7:31 PM
$VTYX My Schwab feed shows Open Interest (which excludes today's volume) on the April 14c at 995 contracts and today's volume at 2406 contracts. Similarly the April 15c had 0 OI and show today's volume at 1399 contracts. Anytime the daily volume exceeds the OI going into the day the volume CAN'T all be closing of existing positions - mathematically, there HAVE TO BE new positions being established (net). Those are not huge bets, but it is nice to see a couple indicators that someone thinks a better bid will be coming.
1 · Reply
stockbuyer1234
stockbuyer1234 Feb. 23 at 3:20 PM
$VTYX High Volume 1.6M already Any thoughts?
1 · Reply
Elevate1
Elevate1 Feb. 23 at 10:02 AM
$VTYX Nvo is facing a real time decision now! Its next generation glp-1 drug did not meet its test standard and did not beat tirzepitide from Lly! If I was this new CEO I would make the move on VTYX! Remember 3232 in combination with semiglutide showed excellent phase 2 results in cardiovascular and liver inflammation. Markets significantly more sizeable than weightloss! few things have been working right lately for the research pipeline! They cannot let Lly get this class of drugs without a fight! Even if they do not come the appraisal rights are worth billions of $. Buying here is a no risk and can be extraordinarily lucrative! But I believe NVO will come this week!
1 · Reply
DragonAlgo
DragonAlgo Feb. 21 at 11:31 AM
🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-03-20 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $4.00 Stop: $2.88 TP1: $5.20 TP2: $6.80 TP3: $9.60 🔗 https://dragonalgo.com
0 · Reply
nsomniyak
nsomniyak Feb. 20 at 7:39 PM
$VTYX I am trying to figure out the motivations of the sellers and buyers here at 13.96 bid 13.97 ask. First some math - using 13.965 as a trade price, the difference between that and the $14 offered by LLY is .26% (just over one quarter of one percent). If I was pretty damn sure the deal was going to go through at 14 I could see selling now if I was looking to take the deal, as the deal will take a a couple months to close after approval. You would get that added .25% in about 3 months - 1% per year - not a very exciting return. Selling now and redeploying capital makes sense if you can earn more than 1% per year elsewhere. However, the flip side is that math does not look great for buyers at 13.965 if they only expect to get $14 in 3 months, as there are LOTS of other ways to 1% per year - just buy T-bills or your broker's money fund. Therefore it seems clear that those buying at 13.965 expect to get more than $14 when all is dais and done.
4 · Reply
nsomniyak
nsomniyak Feb. 20 at 5:32 PM
$VTYX VTYX volume has reached the daily average. Additonally, I see 64K shares on the top bid and 128K shares on the low ask. I have not been tracking bid and ask sizes - but that seems like a lot. Has anyone been following the inside bid and ask sizes? I so could you offer your perscpective?
0 · Reply
Elevate1
Elevate1 Feb. 20 at 2:28 PM
$VTYX How about no downside, high probability of higher bid and huge opportunity to win in appraisal and share with less people. This is a no lose situation I am long and will def ask for appraisal but also will trade at will!
1 · Reply
Latest News on VTYX
Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

Jan 21, 2026, 2:42 PM EST - 4 weeks ago

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

SNCY

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

Jan 8, 2026, 11:44 AM EST - 6 weeks ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

Pharma stocks are set to take off this year, says UBS' Michael Yee

Jan 8, 2026, 11:01 AM EST - 6 weeks ago

Pharma stocks are set to take off this year, says UBS' Michael Yee

IBB LLY

Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal

Jan 7, 2026, 4:25 PM EST - 6 weeks ago

Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal

LLY

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

Jan 7, 2026, 4:17 PM EST - 6 weeks ago

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

LLY

Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports

Jan 6, 2026, 3:48 PM EST - 6 weeks ago

Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports

LLY

Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter

Jan 6, 2026, 3:40 PM EST - 6 weeks ago

Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter

LLY

Ventyx Provides Clinical and Corporate Updates

Dec 2, 2025, 7:02 AM EST - 2 months ago

Ventyx Provides Clinical and Corporate Updates

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:02 AM EST - 3 months ago

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Nov 17, 2025, 7:02 AM EST - 3 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Nov 6, 2025, 4:02 PM EST - 3 months ago

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript

Oct 24, 2025, 2:17 AM EDT - 4 months ago

Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Oct 22, 2025, 4:02 PM EDT - 4 months ago

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Aug 27, 2025, 7:02 AM EDT - 6 months ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Jun 17, 2025, 7:00 AM EDT - 8 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 9 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

May 8, 2025, 4:01 PM EDT - 10 months ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Apr 1, 2025, 7:00 AM EDT - 11 months ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Feb 27, 2025, 4:05 PM EST - 1 year ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Feb 18, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Jan 14, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Nov 4, 2024, 10:32 AM EST - 1 year ago

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

Sep 23, 2024, 11:13 AM EDT - 1 year ago

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

SNY

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Ventyx Biosciences Announces Departure of Chief Financial Officer

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Jul 29, 2024, 2:31 PM EDT - 1 year ago

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

Jul 29, 2024, 11:03 AM EDT - 1 year ago

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

Jun 24, 2024, 6:00 AM EDT - 1 year ago

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

Jun 21, 2024, 4:15 PM EDT - 1 year ago

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

Jun 20, 2024, 7:20 AM EDT - 1 year ago

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

Jun 19, 2024, 4:20 PM EDT - 1 year ago

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

Jun 18, 2024, 3:42 PM EDT - 1 year ago

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 17, 2024, 6:32 AM EDT - 1 year ago

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 4:06 PM EDT - 1 year ago

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 8:17 PM
$VTYX RSI: 50.00, MACD: 0.4325 Vol: 0.02, MA20: 13.95, MA50: 12.03 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Etiennec
Etiennec Feb. 23 at 7:59 PM
$VTYX
0 · Reply
Agafon12
Agafon12 Feb. 23 at 7:57 PM
$VTYX Great news for Novo — down 16% today. If anyone has their phone number, call them and tell them there’s Ventyx they can buy for cheap.
0 · Reply
nsomniyak
nsomniyak Feb. 23 at 7:31 PM
$VTYX My Schwab feed shows Open Interest (which excludes today's volume) on the April 14c at 995 contracts and today's volume at 2406 contracts. Similarly the April 15c had 0 OI and show today's volume at 1399 contracts. Anytime the daily volume exceeds the OI going into the day the volume CAN'T all be closing of existing positions - mathematically, there HAVE TO BE new positions being established (net). Those are not huge bets, but it is nice to see a couple indicators that someone thinks a better bid will be coming.
1 · Reply
stockbuyer1234
stockbuyer1234 Feb. 23 at 3:20 PM
$VTYX High Volume 1.6M already Any thoughts?
1 · Reply
Elevate1
Elevate1 Feb. 23 at 10:02 AM
$VTYX Nvo is facing a real time decision now! Its next generation glp-1 drug did not meet its test standard and did not beat tirzepitide from Lly! If I was this new CEO I would make the move on VTYX! Remember 3232 in combination with semiglutide showed excellent phase 2 results in cardiovascular and liver inflammation. Markets significantly more sizeable than weightloss! few things have been working right lately for the research pipeline! They cannot let Lly get this class of drugs without a fight! Even if they do not come the appraisal rights are worth billions of $. Buying here is a no risk and can be extraordinarily lucrative! But I believe NVO will come this week!
1 · Reply
DragonAlgo
DragonAlgo Feb. 21 at 11:31 AM
🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-03-20 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $4.00 Stop: $2.88 TP1: $5.20 TP2: $6.80 TP3: $9.60 🔗 https://dragonalgo.com
0 · Reply
nsomniyak
nsomniyak Feb. 20 at 7:39 PM
$VTYX I am trying to figure out the motivations of the sellers and buyers here at 13.96 bid 13.97 ask. First some math - using 13.965 as a trade price, the difference between that and the $14 offered by LLY is .26% (just over one quarter of one percent). If I was pretty damn sure the deal was going to go through at 14 I could see selling now if I was looking to take the deal, as the deal will take a a couple months to close after approval. You would get that added .25% in about 3 months - 1% per year - not a very exciting return. Selling now and redeploying capital makes sense if you can earn more than 1% per year elsewhere. However, the flip side is that math does not look great for buyers at 13.965 if they only expect to get $14 in 3 months, as there are LOTS of other ways to 1% per year - just buy T-bills or your broker's money fund. Therefore it seems clear that those buying at 13.965 expect to get more than $14 when all is dais and done.
4 · Reply
nsomniyak
nsomniyak Feb. 20 at 5:32 PM
$VTYX VTYX volume has reached the daily average. Additonally, I see 64K shares on the top bid and 128K shares on the low ask. I have not been tracking bid and ask sizes - but that seems like a lot. Has anyone been following the inside bid and ask sizes? I so could you offer your perscpective?
0 · Reply
Elevate1
Elevate1 Feb. 20 at 2:28 PM
$VTYX How about no downside, high probability of higher bid and huge opportunity to win in appraisal and share with less people. This is a no lose situation I am long and will def ask for appraisal but also will trade at will!
1 · Reply
DragonAlgo
DragonAlgo Feb. 20 at 1:31 PM
🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-02-20 | Strike: $14.00 | Type: CALL Option Plan (premium): Entry: $0.03 Stop: $0.02 TP1: $0.04 TP2: $0.05 TP3: $0.07 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
Agafon12
Agafon12 Feb. 20 at 11:38 AM
$VTYX Trying to understand the logic here. If VTX2735 in recurrent pericarditis isn’t working, why extend/expand the Phase 2 and keep engaging with the FDA? But if it is working, why agree to sell the company so cheap and schedule the shareholder vote before VTX2735 results? What’s the rational explanation for this timeline?
1 · Reply
nakedbutnotshort2
nakedbutnotshort2 Feb. 20 at 3:54 AM
$VTYX Glazer Capital's Likely Objectives Given Glazer’s history, their 6% ownership is likely focused on two main goals: Capturing the Merger Spread: Arbitrageurs buy shares after a deal is announced to capture the "spread"—the difference between the current market price and the $14.00 buyout price. As of February 13, 2026, VTYX was trading at approximately $13.97, very close to the offer price. Ensuring Deal Completion: With a 6% stake, Glazer has a significant vote in the upcoming stockholder meeting. Ventyx has scheduled a vote for March 3, 2026, to approve the merger. Glazer typically supports deals they invest in once they are satisfied with the terms.
1 · Reply
nakedbutnotshort2
nakedbutnotshort2 Feb. 20 at 3:48 AM
$VTYX Glazer Capital's core Investment Strategies The firm employs several types of arbitrage and event-driven techniques, including: Merger Arbitrage (Risk Arbitrage): Investing in the stocks of companies involved in announced mergers and acquisitions to capture the price spread.
1 · Reply
Elevate1
Elevate1 Feb. 19 at 11:47 PM
$VTYX Glazer is one of the best arb funds I guess he agrees with me! I am Long and will trade at will
0 · Reply
Agafon12
Agafon12 Feb. 19 at 10:06 PM
$VTYX Glazer Capital, LLC bought Ventyx shares. Now that is interesting!
0 · Reply
DragonAlgo
DragonAlgo Feb. 19 at 6:49 PM
🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-02-20 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $3.85 Stop: $2.77 TP1: $5.00 TP2: $6.54 TP3: $9.24 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Elevate1
Elevate1 Feb. 19 at 11:45 AM
$VTYX
1 · Reply
Elevate1
Elevate1 Feb. 18 at 10:22 PM
$VTYX Interesting volume surge at day’s end . We shall see they were coming for it
0 · Reply
DragonAlgo
DragonAlgo Feb. 18 at 9:38 PM
🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-02-20 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $3.75 Stop: $2.70 TP1: $4.88 TP2: $6.38 TP3: $9.00 🔗 https://dragonalgo.com
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 7:52 PM
$VTYX Current Stock Price: $13.95 Contracts to trade: $14.0 VTYX Feb 20 2026 Call Entry: $0.03 Exit: $0.04 ROI: 42% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Etiennec
Etiennec Feb. 18 at 3:03 PM
$VTYX Yesterday, 70 institutional bought/sold — that’s more than all the transactions since the beginning of the year, in a single day. I don’t know what’s going on, but something is definitely happening.
3 · Reply